Hemostat reconstitution methods and devices

Patent metadata

Field	Value
Publication number	US-12343385-B2
Application number	US-202217985427-A
Country	US
Kind code	B2
Filing date	Nov 11, 2022
Priority date	Nov 29, 2021
Publication date	Jul 1, 2025
Grant date	Jul 1, 2025

Abstract

A kit and system for use in establishing local hemostasis includes a first and a second syringe. The first syringe is co-loaded with at least one substrate material and at least one hemostatic agent including a membrane separating the substrate material and the hemostatic agent. The second syringe is loaded with a diluent. In an embodiment, the kit or system includes crosslinked gelatin particles and thrombin, and the diluent is saline.

First claim

The invention claimed is:

1. A system for administering a hemostatic material to a patient, the system comprising;
a first syringe co-loaded with at least one substrate material and at least one hemostatic agent including a membrane separating said substrate material and said hemostatic agent; and
a second syringe loaded with a diluent.

2. The system of claim 1 , wherein said at least one substrate material comprises a gelatin.

3. The system of claim 2 , wherein said gelatin comprises a cross-linked gelatin.

4. The system of claim 3 , wherein said cross-linked gelatin comprises gelatin granules.

5. The system of claim 1 , wherein said at least one hemostatic agent comprises thrombin.

6. The system of claim 1 , wherein said diluent comprises sterile water.

7. The system of claim 1 , wherein said diluent comprises saline.

8. The system of claim 7 , wherein said saline comprises 0.9% (w/v) NaCl.

9. The system of claim 1 , wherein said substrate material is pre-swollen.

10. The system of claim 1 , wherein said membrane comprises a dissolvable, fragmentable, or friable material.

11. The system of claim 10 , wherein said dissolvable, fragmentable, or friable material comprises a gelatin.

12. A kit for use in establishing local hemostasis, comprising;
a first syringe co-loaded with at least one substrate material and at least one hemostatic agent including a membrane separating said substrate material and said hemostatic agent; and
a second syringe loaded with a diluent.

13. The kit of claim 12 , wherein said at least one substrate material comprises a gelatin.

14. The kit of claim 13 , wherein said gelatin comprises a cross-linked gelatin.

15. The kit of claim 14 , wherein said cross-linked gelatin comprises gelatin granules.

16. The kit of claim 12 , wherein said at least one hemostatic agent comprises thrombin.

17. The kit of claim 12 , wherein said diluent comprises sterile water.

18. The kit of claim 12 , wherein said diluent comprises saline.

19. The kit of claim 18 , wherein said saline comprises 0.9% (w/v) NaCl.

20. The kit of claim 12 , wherein said substrate material is pre-swollen.

Assignees

• Baxter Int
• Baxter Healthcare Sa
• Baxtter Healthcare SA

Inventors

• Delmotte Yves

Classifications

• A61L2400/04

  Materials for stopping bleeding · CPC title

• A61L24/0031

  Hydrogels or hydrocolloids · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61K35/08

  Mineral waters; Sea water · CPC title

• A61K38/014

  from connective tissue peptides, e.g. gelatin, collagen · CPC title